S&P 500 Futures
(-0.08%) 5 304.25 points
Dow J Futures
(-0.09%) 40 140 points
Nasdaq Futures
(-0.05%) 18 465 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(0.21%) $923.00
USD/EUR
(0.15%) $0.928
USD/NOK
(0.25%) $10.87
USD/GBP
(0.00%) $0.792
USD/RUB
(-0.23%) $92.36

Realtime updates for RaQualia Pharma Inc. [4579.T]

Exchange: JPX Sector: Healthcare Industry: Biotechnology
Last Updated29 Mar 2024 @ 02:15

2.66% ¥ 618.00

Live Chart Being Loaded With Signals

Commentary (29 Mar 2024 @ 02:15):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 1 clinical trial in the United States; and grapiprant for pain management, which is in phase II clinical trial in the United States and phase I clinical trial in China, as well as in phase I clinical trial in China and the United States to treat cancer...

Stats
Today's Volume 93 600.00
Average Volume 131 075
Market Cap 13.36B
EPS ¥0 ( 2024-02-14 )
Next earnings date ( ¥0 ) 2024-05-12
Last Dividend ¥0 ( N/A )
Next Dividend ¥0 ( N/A )
P/E 91.69
ATR14 ¥1.084 (0.18%)

Volume Correlation

Long: -0.21 (neutral)
Short: 0.00 (neutral)
Signal:(57.542) Neutral

RaQualia Pharma Inc. Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

RaQualia Pharma Inc. Correlation - Currency/Commodity

The country flag 0.52
( weak )
The country flag 0.62
( weak )
The country flag -0.10
( neutral )
The country flag 0.70
( moderate )
The country flag -0.68
( moderate negative )
The country flag -0.68
( moderate negative )

RaQualia Pharma Inc. Financials

Annual 2023
Revenue: ¥1.90B
Gross Profit: ¥1.48B (77.88 %)
EPS: ¥-14.98
Q4 2023
Revenue: ¥405.71M
Gross Profit: ¥295.02M (72.72 %)
EPS: ¥-9.53
Q3 2023
Revenue: ¥481.41M
Gross Profit: ¥414.27M (86.05 %)
EPS: ¥-6.62
Q2 2023
Revenue: ¥643.59M
Gross Profit: ¥580.74M (90.23 %)
EPS: ¥8.00

Financial Reports:

No articles found.

RaQualia Pharma Inc.

RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 1 clinical trial in the United States; and grapiprant for pain management, which is in phase II clinical trial in the United States and phase I clinical trial in China, as well as in phase I clinical trial in China and the United States to treat cancer. The company also provides veterinary products such as, grapiprant for osteoarthritis in dogs; ghrelin receptor agonist to treat cancer-related anorexia/cachexia syndrome, and constipation resulting from spinal cord injury; and ELURA, a drug for the management of weight loss in cats with chronic kidney disease. In addition, it provides TRPM8 blocker for the target indication of neuropathic pain; motilin receptor agonist to treat gastrointestinal dysmotility, including gastroparesis, functional dyspepsia, and post-operative ileus; potassium-competitive acid blocker to treat gastro-esophageal reflux disease that has completed phase 1 clinical trial; 5-HT4 partial agonist to treat gastroparesis, functional dyspepsia, and chronic constipation; 5-HT2B antagonist to treat irritable bowel syndrome with diarrhea; EP4 antagonist, a pain management drugs for dogs; serotonin 5-HT2A and dopamine D2 receptor blocker to treat schizophrenia; EP4 antagonist to treat cancer that is in phase I clinical trial, as well as in phase 1 clinical trial for the indication of pain; Cyclooxygenase-2 inhibitor, Phase I clinical trials for the indication of pain; CB2 agonist; selective sodium channel blocker; P2X7 receptor antagonist, which is in Phase I clinical trials for the target indication of neuropathic pain; and retinoic acid receptor alpha agonist. It has a collaborative agreement with Interprotein Corporation, ASKA Pharmaceutical. Co., Ltd., and Epigeneron, Inc. The company was incorporated in 2008 and is headquartered in Nagoya, Japan.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators